<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938886</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAA-17181-1</org_study_id>
    <nct_id>NCT00938886</nct_id>
  </id_info>
  <brief_title>Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment</brief_title>
  <official_title>Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test whether naltrexone compared to placebo can reduce heavy drinking and improve smoking
      cessation outcomes in heavy drinkers seeking smoking cessation treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A substantial portion of individuals seeking behavioral and pharmacological treatment for
      smoking cessation drink excessively with many reporting significant alcohol problems.
      Although these at-risk and problem drinkers are unlikely to choose abstinence from alcohol as
      a goal, many make substantial reductions in their drinking during and after their quit
      smoking attempt. Thus, the context of smoking cessation treatment offers a unique and
      valuable opportunity in which to apply brief interventions and pharmacotherapy to catalyze
      change in excessive drinking in a population with markedly elevated risk for negative health
      outcomes. In our recent randomized clinical trial, standard smoking cessation treatment that
      incorporated a brief alcohol intervention showed promise in reducing drinking as well as in
      improving smoking cessation outcomes among heavy drinkers. However, these effects were
      relatively modest, especially among the heaviest drinkers, indicating that further study is
      warranted of methods to address heavy drinking in smoking cessation including the use of
      relevant pharmacotherapy. Naltrexone, in particular, shows promise for this purpose.

      The overall aim of this project is to test the efficacy of naltrexone as a pharmacotherapy
      for excessive drinking when delivered to at-risk or problem drinkers who are seeking smoking
      cessation treatment. The proposed clinical trial uses a between-subjects design in which 300
      at-risk or problem drinkers seeking treatment for smoking cessation will be randomly assigned
      to receive either daily 50 mg naltrexone or placebo. Medication will be initiated 2 weeks
      prior to participants' smoking quit date and continue for 10 weeks. All participants also
      will receive transdermal nicotine patch and a counseling and medication management
      intervention that provides advice for smoking cessation, advice regarding the effects of
      heavy drinking on both smoking cessation and health, and monitoring and encouragement of
      compliance with medications. Drinking and smoking outcomes will be assessed at 2, 8, 16, and
      26 weeks after participants' smoking quit date. The primary aim of the study is to test the
      hypothesis that naltrexone will result in greater reductions in heavy drinking relative to
      placebo. The secondary aim will test whether naltrexone results in superior smoking outcomes
      relative to placebo, and tertiary aims will examine interrelationships among motivation for
      changing drinking, compliance with naltrexone, and drinking and smoking outcomes.

      This study represents the first of its kind to provide naltrexone in conjunction with an
      opportunistic brief alcohol intervention for at-risk and problem drinkers not seeking alcohol
      treatment. Testing the potential benefits of naltrexone among at-risk and problem drinkers
      who smoke is of very high significance for public health efforts to reduce the markedly
      elevated rates of morbidity and mortality observed in this large, yet relatively understudied
      group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Heavy Drinking Days</measure>
    <time_frame>Across the 6 months following smoking quit date</time_frame>
    <description>Defined for women as percent of days drinking 4 or more drinks in a day. For men, percent of days drinking 5 or more drinks in a day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>7-day Point Prevalence Smoking Abstinence</measure>
    <time_frame>26 weeks after target quit smoking date</time_frame>
    <description>Self-report abstinence from smoking over the past 7 days biochemically confirmed with carbon monoxide and saliva cotinine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Hazardous Drinking</condition>
  <condition>Cigarette Smoking</condition>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg daily naltrexone for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily matched placebo pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Daily 50 mg naltrexone</description>
    <arm_group_label>Naltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched naltrexone placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.) be at least 18 years of age, 2.) drink heavily at least once per month on average
             (≥4 drinks per occasion for women; ≥5 drinks for men), 3.) have smoked cigarettes
             regularly for at least one year, 4.) currently smoke at least 5 cigarettes a day, 5.)
             currently be using no other tobacco products or nicotine replacement therapy

        Exclusion Criteria:

          -  1.) meet criteria for current substance dependence (excluding nicotine and alcohol);
             2.) report opiate use in the past month, have a drug screen positive for opiates, or
             require opiate containing medications for pain management; 3.) meet criteria for a
             current major depressive or manic episode; 4.) are currently psychotic or suicidal;
             5.) have an unstable or serious medical condition that would preclude use of the
             nicotine patch or naltrexone (e.g., unstable angina pectoris, severe arrhythmia,
             recent congestive heart failure); 6.) have aspartate aminotransferase or alanine
             aminotransferase levels of more than 3 times the reference range or elevated bilirubin
             levels; or 7.) are currently pregnant or lactating, intend to become pregnant, or are
             not using a reliable means of birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher W. Kahler, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2009</study_first_submitted>
  <study_first_submitted_qc>July 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2009</study_first_posted>
  <results_first_submitted>February 22, 2017</results_first_submitted>
  <results_first_submitted_qc>April 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2017</results_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Christopher W. Kahler</investigator_full_name>
    <investigator_title>Professor of Behavioral and Social Sciences</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from Providence, RI and the surrounding community through bulletin board, radio, internet, newspaper, and public transportation advertisements.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone</title>
          <description>50 mg daily naltrexone for 10 weeks
Naltrexone: Daily 50 mg naltrexone</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Daily matched placebo pill
Placebo: Matched naltrexone placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Attended 1 Counseling Session</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone</title>
          <description>50 mg daily naltrexone for 10 weeks
Naltrexone: Daily 50 mg naltrexone</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Daily matched placebo pill
Placebo: Matched naltrexone placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="12.7"/>
                    <measurement group_id="B2" value="41.8" spread="12.9"/>
                    <measurement group_id="B3" value="42.1" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Alcohol Dependence</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fagerstrom Test for Nicotine Dependence</title>
          <description>Scale ranges from 0 to 10 where higher values indicates higher levels of nicotine dependence.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" spread="2.2"/>
                    <measurement group_id="B2" value="5.4" spread="2.3"/>
                    <measurement group_id="B3" value="5.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Heavy Drinking Days</title>
        <description>Defined for women as percent of days drinking 4 or more drinks in a day. For men, percent of days drinking 5 or more drinks in a day</description>
        <time_frame>Across the 6 months following smoking quit date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone</title>
            <description>50 mg daily naltrexone for 10 weeks
Naltrexone: Daily 50 mg naltrexone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily matched placebo pill
Placebo: Matched naltrexone placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Heavy Drinking Days</title>
          <description>Defined for women as percent of days drinking 4 or more drinks in a day. For men, percent of days drinking 5 or more drinks in a day</description>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="13.1"/>
                    <measurement group_id="O2" value="11.4" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7-day Point Prevalence Smoking Abstinence</title>
        <description>Self-report abstinence from smoking over the past 7 days biochemically confirmed with carbon monoxide and saliva cotinine.</description>
        <time_frame>26 weeks after target quit smoking date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone</title>
            <description>50 mg daily naltrexone for 10 weeks
Naltrexone: Daily 50 mg naltrexone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily matched placebo pill
Placebo: Matched naltrexone placebo</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence Smoking Abstinence</title>
          <description>Self-report abstinence from smoking over the past 7 days biochemically confirmed with carbon monoxide and saliva cotinine.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone</title>
          <description>50 mg daily naltrexone for 10 weeks
Naltrexone: Daily 50 mg naltrexone</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Daily matched placebo pill
Placebo: Matched naltrexone placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Appendectomy</sub_title>
                <description>Emergency appendectomy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Surgery</sub_title>
                <description>Back surgery to relieve acute nerve problem</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Adbominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="75"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher Kahler</name_or_title>
      <organization>Brown University</organization>
      <phone>401 863-6651</phone>
      <email>christopher_kahler@brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

